Home › Funds › Novo Holdings A/S › CLDX
Novo Holdings A/S position in CLDX
CELLDEX THERAPEUTICS INC NEW · Health Care
Novo Holdings A/S reported holding 950,000 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q3 2026 13F filing — a position valued at US$30.8M, representing 2.07% of its reported portfolio and ranking #16 among its reported holdings. Novo Holdings A/S has disclosed CLDX holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Novo Holdings A/S's CLDX position evolved
Novo Holdings A/S first disclosed a stake in CLDX in Q2 2024 at 850,000 shares (US$31.5M). The position peaked in Q2 2026 at 1,025,000 shares, worth US$38.1M. Across 10 filings, Novo Holdings A/S increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 950,000 shares valued at US$30.8M — a reduction of -75,000 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 850.00K | $31.46M | New |
| Q3 2024 | 963.66K | $32.75M | Add |
| Q4 2024 | 1.00M | $25.27M | Add |
| Q1 2025 | 1.20M | $21.78M | Add |
| Q2 2025 | 1.20M | $24.42M | Hold |
| Q3 2025 | 1.20M | $31.04M | Hold |
| Q4 2025 | 1.20M | $32.59M | Hold |
| Q1 2026 | 1.20M | $38.06M | Hold |
| Q2 2026 | 1.02M | $38.14M | Reduce |
| Q3 2026 | 950.00K | $30.79M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CLDX and 13F data
CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 35 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$164.2M), BAKER BROS. ADVISORS LP (US$83.1M), Deep Track Capital, LP (US$68.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CLDX
- Kynam Capital Management, LP 5.07M sh · $164.19M · Q3 2026
- BAKER BROS. ADVISORS LP 2.56M sh · $83.13M · Q3 2026
- Deep Track Capital, LP 2.13M sh · $68.89M · Q3 2026
- EVENTIDE ASSET MANAGEMENT, LLC 1.90M sh · $61.46M · Q3 2026
- Eversept Partners, LP 1.17M sh · $38.07M · Q3 2026
- Affinity Asset Advisors, LLC 1.16M sh · $37.61M · Q3 2026
- Elmind Capital, LP 1.11M sh · $35.98M · Q3 2026
- Commodore Capital LP 1.00M sh · $32.41M · Q3 2026
- Frazier Life Sciences Management, L.P. 900.08K sh · $29.17M · Q3 2026
- ADAR1 Capital Management, LLC 799.30K sh · $25.91M · Q3 2026
- Trails Edge Capital Partners, LP 765.00K sh · $24.79M · Q3 2026
More on Novo Holdings A/S
FAQ
How long has Novo Holdings A/S held CLDX?
Novo Holdings A/S has disclosed CLDX holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
What is Novo Holdings A/S's current position in CLDX?
As of Q3 2026, Novo Holdings A/S holds 950.00K shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $30.79M, representing 2.07% of its reported portfolio and ranking #16.
Has Novo Holdings A/S been buying or selling CLDX?
In the latest 13F filing (Q3 2026), Novo Holdings A/S reduced its position in CLDX. The position peaked in Q2 2026 at 1.02M shares.
Which other funds hold CLDX?
Other major institutional holders of CLDX include Kynam Capital Management, LP, BAKER BROS. ADVISORS LP, Deep Track Capital, LP, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.